| technetium | <radiology> Tc-99m, half-life: 6.03 hr, decay: isomeric transition, radiation: gamma, 140 keV (98%) (12 Dec 1998) |
|---|---|
| technetium compounds | Inorganic compounds that contain technetium as an integral part of the molecule. (12 Dec 1998) |
| technetium tc 99m aggregated albumin | <chemical> A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in cardiovascular and cerebral circulation. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m diethyl-iminodiacetic acid | <chemical> A nontoxic radiopharmaceutical that is used in the clinical evaluation of hepatobiliary disorders in humans. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m dimercaptosuccinic acid | <chemical> A nontoxic radiopharmaceutical that is used in the diagnostic imaging of the renal cortex. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m disofenin | <chemical> A radiopharmaceutical used extensively in cholescintigraphy for the evaluation of hepatobiliary diseases. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m exametazime | <chemical> A gamma-emitting radionuclide imaging agent used in the evaluation of regional cerebral blood flow and in non-invasive dynamic biodistribution studies and myocardial imaging. It has also been used to label leukocytes in the investigation of inflammatory bowel diseases. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m lidofenin | <chemical> A nontoxic radiopharmaceutical that is used in the clinical evaluation of hepatobiliary disorders in humans. (j nucl med 1977;18(10):997-1004) Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m medronate | <chemical> A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumours, it is useful for the detection of neoplasms. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium tc 99m mertiatide | <chemical> A technetium diagnostic aid used in renal function determination. Pharmacological action: radiopharmaceuticals. Chemical name: Technetate(2-)-99Tc, (N-(N-(N-(mercaptoacetyl)glycyl)glycyl)glycinato(5-)-N,N',N'',S)oxo-, disodium, (SP-5-25)- (12 Dec 1998) |
| technetium tc 99m pentetate | <chemical> A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents. Pharmacological action: chelating agents, radiopharmaceuticals. Chemical name: Technetate(1-)-99Tc, (N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))-, sodium (12 Dec 1998) |
| technetium tc 99m pyrophosphate | <chemical> A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. Pharmacological action: radiopharmaceuticals, (12 Dec 1998) |
| technetium tc 99m sestamibi | <chemical> (oc-6-11)-hexakis(1-isocyano-2-methoxy-2-methylpropane)technetium(1+)-99mtc. A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack. Pharmacological action: radiopharmaceuticals. Chemical name: Technetium(1+)-99Tc, hexakis(1-isocyano-2-methoxy-2-methylpropane)-, (OC-6-11)- (12 Dec 1998) |
| technetium tc 99m sulfur colloid | <chemical> A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, liver, and spleen. Pharmacological action: radiopharmaceuticals. (12 Dec 1998) |
| technetium-99 | A radioisotope of technetium which is the decay product of technetium-99m and has a weak beta emission and a physical half-life of 213,000 years. (05 Mar 2000) |
| vena-tech ivc filter | <radiology> Introduced as LGM (L.G. Medical, France), 1985; FDA aprroval 1991: Vena-Tech, Evanston, IL, 6-leg conical design with 6 stabilizing side bars, biocompatible metal known as Phynox (cobalt,chromium,iron,nickel,moly) Efficacy, recurrent PE: 2-6%, IVC occlusion: 8-24%, migration: 0-12% Advantages, ease of placement, excellent clot trapping efficiency, low profile, lacks ferromagnetic activity: minimal MRI artifacts Disadvantages, incomplete opening (6-19%): decreases clot-trapping efficiency, increased incidence from IJ approach, decreased with rapid deployment, increased IVC thrombosis rates: 8% initial reports; 22-24% on subsequent reports by ultrasound/MRI: 2-19% clinically symptomatic (12 Dec 1998) |
|---|